Citius Pharmaceuticals Inc vs SAP SE — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while SAP SE trades at $206.8 (market cap $240.81B). The key difference: SAP SE is far larger — about 12034.5× Citius Pharmaceuticals Inc's market cap, and SAP SE pays a 1.4% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SAP | |
|---|---|---|
Market Cap | $20.01M | $240.81B |
Sector | Health | Technology |
52-Week High | $1.82 | $280.46 |
52-Week Low | $0.48 | $146.38 |
Enterprise Value | $16.23M | $239.52B |
Dividend Yield | — | 1.4% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
No Aura AI signal available yet.
Trailing returns across standard periods
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →